Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Caulobacter expression of human intracellular protein therapeutic candidates

EF 2011-12

Résumé
iProgen Inc. is an early stage biotechnology company (located in Richmond, BC) engaged in the development of protein drugs for the treatment of human diseases. Protein therapeutics represent the fastest growing segment of the biopharmaceutical market, which is expected to reach a global value of $77 billion by 2011. Today, almost all of the protein therapeutics sold are extracellular proteins that function from outside the cell. However, this extracellular class represents only 14% of the potential proteins available for therapeutics development. The difficulty with protein therapeutics with intracellular targets is the inability to effectively deliver them to the inside of the cell. iProgen's technology addresses this barrier through the design and development of novel protein delivery tags (PTMs), which enable proteins to enter particular cell types. iProgen has made significant progress in developing the process for producing PTM-tagged proteins. However, the inability to produce intracellular proteins with human cell lines has become a major bottleneck in developing the commercial potential of the technology. All candidate proteins are biologically active within human cells and when expressed at high levels they become toxic and kill the production cell lines. Therefore, iProgen is seeking another non-human cell based expression system to solve its production problem. The protein secretion system that mediates export of a major surface protein of the bacterium Caulobacter crescentus has been used to secrete a wide variety of recombinant proteins, often at high levels. Here we propose to adapt the system for production of human gene transcription and regulatory factors, which would subsequently be modified by PTMs for intracellular delivery. Success in this project would relieve a key process bottleneck and allow commercialization of the iProgen technology.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
418968-2011
Name nom
Smit, John
Department département
Microbiology and Immunology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5305
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Protein manipulation and expression
Research subject fr
Expression et recombinaison protéiques
Partie
1
Nb partie
1
Application title
Caulobacter expression of human intracellular protein therapeutic candidates
Keyword
NSERC
Application summary
iProgen Inc. is an early stage biotechnology company (located in Richmond, BC) engaged in the development of protein drugs for the treatment of human diseases. Protein therapeutics represent the fastest growing segment of the biopharmaceutical market, which is expected to reach a global value of $77 billion by 2011. Today, almost all of the protein therapeutics sold are extracellular proteins that function from outside the cell. However, this extracellular class represents only 14% of the potential proteins available for therapeutics development. The difficulty with protein therapeutics with intracellular targets is the inability to effectively deliver them to the inside of the cell. iProgen's technology addresses this barrier through the design and development of novel protein delivery tags (PTMs), which enable proteins to enter particular cell types. iProgen has made significant progress in developing the process for producing PTM-tagged proteins. However, the inability to produce intracellular proteins with human cell lines has become a major bottleneck in developing the commercial potential of the technology. All candidate proteins are biologically active within human cells and when expressed at high levels they become toxic and kill the production cell lines. Therefore, iProgen is seeking another non-human cell based expression system to solve its production problem. The protein secretion system that mediates export of a major surface protein of the bacterium Caulobacter crescentus has been used to secrete a wide variety of recombinant proteins, often at high levels. Here we propose to adapt the system for production of human gene transcription and regulatory factors, which would subsequently be modified by PTMs for intracellular delivery. Success in this project would relieve a key process bottleneck and allow commercialization of the iProgen technology.